PFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Pfizer Inc's research and development for the three months ended in Dec. 2014 was $3,209 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2014 was $8,393 Mil.
This is the expense the company spent on research and development.
Pfizer Inc Research & Development for the trailing twelve months (TTM) ended in Dec. 2014 was 1623 (Mar. 2014 ) + 1759 (Jun. 2014 ) + 1802 (Sep. 2014 ) + 3209 (Dec. 2014 ) = $8,393 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Pfizer Inc Annual Data
|Research & Development||7,256||7,599||8,089||8,578||7,913||9,413||9,112||7,870||6,678||8,393|
Pfizer Inc Quarterly Data
|Research & Development||1,981||2,136||1,800||1,530||1,627||1,811||1,623||1,759||1,802||3,209|